
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Dr Antonio Martorell is a dermatologist at the Hospital de Manises in Valencia, Spain, and an Associate Professor of dermatology at the Catholic University of Valencia. He founded and leads a specialised unit focused mainly on the management of patients with psoriasis, hidradenitis suppurativa and related comorbidities.
Dr Martorell received his degree in medicine and surgery from the University of Valencia and specialised in dermatology at Hospital Instituto Valenciano de Oncología, Valencia, an international reference centre in surgery and oncology.
Dr Martorell’s main scientific areas of interest are psoriasis, hidradenitis suppurativa and hair disorders. His recent research has focused on the epigenetic pathways of hidradenitis suppurativa and skin ultrasound, and he is the founder of the DERMUS Task Force. Dr Martorell has authored 217 PubMed articles and has been the invited speaker for 351 lectures covering topics including psoriasis, hidradenitis suppurativa and skin cancer. He is also the Principal Investigator of over 20 clinical assays in phase II, III and IV clinical trials. In addition, Dr Martorell is the founder and coordinator of the Spanish Working Group on Hidradenitis Suppurativa (GTHS), and since 2022, he has led the innovation and research area of the Spanish Academy of Dermatology and Venereology (AEDV). Dr Martorell is also director of the IADERMA course leading a group focused on eHealth oriented to the development of ICT solutions with the aim of improving basic medical procedures during this new technological era. Dr Martorell holds the position of health manager and project coordinator at E-health in SKIANA®.
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.
Read our key takeaways from the 2022 ASAS-EULAR recommendations for the management of axSpA, presented as part of Dr Sofia Ramiro's workshop at UCB Summit 2023.